Table 2

Time in study and drug exposure

Placebo (n=116)Lebrikizumab 37.5 mg (n=117)Lebrikizumab 125 mg (n=112)Lebrikizumab 250 mg (n=118)
LUTE, n (%)66 (56.9)64 (54.7)62 (55.4)66 (55.9)
VERSE, n (%)50 (43.1)53 (45.3)50 (44.6)52 (44.1)
Time in placebo-controlled period (weeks)
 Median24.124.128.124.1
 <12, n (%)17 (14.7)21 (17.9)13 (11.6)22 (18.6)
 12 to <24, n (%)34 (29.3)33 (28.2)31 (27.7)35 (29.7)
 24 to <36, n (%)37 (31.9)37 (31.6)33 (29.5)31 (26.3)
 ≥36, n (%)28 (24.1)26 (22.2)35 (31.3)30 (25.4)
Time in study (weeks)
 Median44.041.044.541.1
 <24, n (%)6 (5.2)10 (8.5)9 (8.0)10 (8.5)
 24 to <36, n (%)28 (24.1)27 (23.1)23 (20.5)31 (26.3)
 ≥36, n (%)82 (70.7)80 (68.4)80 (71.4)77 (65.3)
Number of doses received
 Median (range)6.0 (2–12)6.0 (1–12)7.0 (1–12)6.0 (1–12)